vs

Side-by-side financial comparison of ALLEGRO MICROSYSTEMS, INC. (ALGM) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $229.2M, roughly 1.4× ALLEGRO MICROSYSTEMS, INC.). ALLEGRO MICROSYSTEMS, INC. runs the higher net margin — 3.6% vs -18.2%, a 21.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 28.9%).

Allegro MicroSystems, Inc. is a global semiconductor firm designing and manufacturing high-performance power and sensing integrated circuits. Its core products include magnetic sensors, power ICs, and motion control solutions, serving automotive, industrial, consumer electronics, and communications markets worldwide.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

ALGM vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.4× larger
MDGL
$321.1M
$229.2M
ALGM
Growing faster (revenue YoY)
MDGL
MDGL
+181.9% gap
MDGL
210.8%
28.9%
ALGM
Higher net margin
ALGM
ALGM
21.9% more per $
ALGM
3.6%
-18.2%
MDGL

Income Statement — Q2 FY2027 vs Q4 FY2025

Metric
ALGM
ALGM
MDGL
MDGL
Revenue
$229.2M
$321.1M
Net Profit
$8.4M
$-58.6M
Gross Margin
46.7%
Operating Margin
57.5%
-18.6%
Net Margin
3.6%
-18.2%
Revenue YoY
28.9%
210.8%
Net Profit YoY
369.0%
1.4%
EPS (diluted)
$0.04
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALGM
ALGM
MDGL
MDGL
Q3 26
$229.2M
Q4 25
$229.2M
$321.1M
Q3 25
$214.3M
$287.3M
Q2 25
$203.4M
$212.8M
Q1 25
$192.8M
$137.3M
Q4 24
$177.9M
$103.3M
Q3 24
$187.4M
$62.2M
Q2 24
$166.9M
Net Profit
ALGM
ALGM
MDGL
MDGL
Q3 26
$8.4M
Q4 25
$8.3M
$-58.6M
Q3 25
$6.5M
$-114.2M
Q2 25
$-13.2M
$-42.3M
Q1 25
$-14.8M
$-73.2M
Q4 24
$-6.9M
$-59.4M
Q3 24
$-33.7M
$-107.0M
Q2 24
$-17.7M
Gross Margin
ALGM
ALGM
MDGL
MDGL
Q3 26
46.7%
Q4 25
46.7%
Q3 25
46.3%
Q2 25
44.9%
Q1 25
41.4%
96.7%
Q4 24
45.7%
Q3 24
45.7%
Q2 24
44.8%
Operating Margin
ALGM
ALGM
MDGL
MDGL
Q3 26
57.5%
Q4 25
4.2%
-18.6%
Q3 25
2.9%
-39.7%
Q2 25
-1.3%
-22.2%
Q1 25
-6.8%
-57.8%
Q4 24
-0.0%
-64.8%
Q3 24
2.2%
-187.1%
Q2 24
-6.4%
Net Margin
ALGM
ALGM
MDGL
MDGL
Q3 26
3.6%
Q4 25
3.6%
-18.2%
Q3 25
3.0%
-39.8%
Q2 25
-6.5%
-19.9%
Q1 25
-7.7%
-53.4%
Q4 24
-3.9%
-57.5%
Q3 24
-18.0%
-172.0%
Q2 24
-10.6%
EPS (diluted)
ALGM
ALGM
MDGL
MDGL
Q3 26
$0.04
Q4 25
$0.04
$-2.55
Q3 25
$0.03
$-5.08
Q2 25
$-0.07
$-1.90
Q1 25
$-0.08
$-3.32
Q4 24
$-0.04
$-2.50
Q3 24
$-0.18
$-4.92
Q2 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALGM
ALGM
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$155.2M
$198.7M
Total DebtLower is stronger
$287.7M
$339.9M
Stockholders' EquityBook value
$602.7M
Total Assets
$1.4B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALGM
ALGM
MDGL
MDGL
Q3 26
$155.2M
Q4 25
$155.2M
$198.7M
Q3 25
$117.5M
$295.7M
Q2 25
$129.1M
$186.2M
Q1 25
$121.3M
$183.6M
Q4 24
$138.5M
$100.0M
Q3 24
$188.8M
$232.7M
Q2 24
$173.1M
Total Debt
ALGM
ALGM
MDGL
MDGL
Q3 26
$287.7M
Q4 25
$280.7M
$339.9M
Q3 25
$280.4M
$339.8M
Q2 25
$304.8M
$118.4M
Q1 25
$338.9M
$118.0M
Q4 24
$368.7M
$117.6M
Q3 24
$393.0M
$117.1M
Q2 24
$195.8M
Stockholders' Equity
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
$962.7M
$602.7M
Q3 25
$944.2M
$625.7M
Q2 25
$922.7M
$696.0M
Q1 25
$929.6M
$710.6M
Q4 24
$933.0M
$754.4M
Q3 24
$937.3M
$777.2M
Q2 24
$1.1B
Total Assets
ALGM
ALGM
MDGL
MDGL
Q3 26
$1.4B
Q4 25
$1.4B
$1.3B
Q3 25
$1.4B
$1.4B
Q2 25
$1.4B
$1.0B
Q1 25
$1.4B
$996.6M
Q4 24
$1.4B
$1.0B
Q3 24
$1.5B
$1.1B
Q2 24
$1.4B
Debt / Equity
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
0.29×
0.56×
Q3 25
0.30×
0.54×
Q2 25
0.33×
0.17×
Q1 25
0.36×
0.17×
Q4 24
0.40×
0.16×
Q3 24
0.42×
0.15×
Q2 24
0.18×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALGM
ALGM
MDGL
MDGL
Operating Cash FlowLast quarter
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
$45.4M
$-133.5M
Q3 25
$20.4M
$79.8M
Q2 25
$61.6M
$-47.1M
Q1 25
$20.4M
$-88.9M
Q4 24
$-8.2M
$-104.5M
Q3 24
$15.5M
$-67.0M
Q2 24
$34.2M
Free Cash Flow
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
$41.3M
$-133.8M
Q3 25
$13.9M
$79.0M
Q2 25
$51.0M
Q1 25
$15.0M
Q4 24
$-21.8M
$-104.7M
Q3 24
$5.6M
$-67.8M
Q2 24
$23.2M
FCF Margin
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
18.0%
-41.7%
Q3 25
6.5%
27.5%
Q2 25
25.1%
Q1 25
7.8%
Q4 24
-12.3%
-101.3%
Q3 24
3.0%
-109.0%
Q2 24
13.9%
Capex Intensity
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
1.8%
0.1%
Q3 25
3.0%
0.3%
Q2 25
5.2%
0.0%
Q1 25
2.8%
0.0%
Q4 24
7.7%
0.2%
Q3 24
5.3%
1.3%
Q2 24
6.6%
Cash Conversion
ALGM
ALGM
MDGL
MDGL
Q3 26
Q4 25
5.47×
Q3 25
3.12×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALGM
ALGM

Automotive$164.5M72%
Industrial and Other$64.7M28%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons